Insider sales
Ugwumba Chidozie, identified as a ten percent owner of Clene Inc. (NASDAQ:CLNN), disposed of a total of 17,909 shares of the company's common stock over a three-day span, according to a Form 4 filing submitted to the Securities and Exchange Commission. The transactions took place on March 24, March 25 and March 26, 2026.
Transaction details show three separate sales: on March 24, Chidozie sold 5,492 shares at $5.78 per share; on March 25, 7,098 shares were sold at $5.50 per share; and on March 26, 5,319 shares were sold at $5.40 per share. The aggregate proceeds from those sales amounted to $99,505, with execution prices ranging from $5.40 to $5.78.
Following these dispositions, the filing indicates that Chidozie retains indirect ownership of 532,091 shares through SymBiosis II, LLC.
Market context
The insider transactions occurred as Clene's shares have declined by 8.2% over the previous week, with the stock quoted at $5.39 at the time of reporting. An InvestingPro tip noted that the stock has experienced a significant drop in the last week while also flagging that, on a Fair Value basis, the company remains undervalued according to that analysis.
Company developments - CNM-Au8 program and financing
In related corporate updates, Clene said it has advanced regulatory engagement for its investigational amyotrophic lateral sclerosis (ALS) treatment, CNM-Au8. The company will hold an in-person Type C meeting with the U.S. Food and Drug Administration later this quarter to review biomarker data tied to the program. The agenda for the meeting emphasizes new analyses suggesting reductions in neurofilament light chain levels may correlate with lower mortality risk in ALS patients, which the company said could support the biomarker's potential use as a surrogate endpoint for accelerated approval.
To support continued development of CNM-Au8, Clene completed a registered direct offering that raised in excess of $28 million. The financing included participation from Boxer Capital, Coastlands Capital, Vivo Capital and existing insider investors. Clene indicated the initial tranche, totaling more than $6 million, is expected to fund operations through the third quarter of 2026, potentially encompassing the FDA's decision on acceptance of a New Drug Application.
What this record shows
The Form 4 filing provides transparent detail on the size, timing and pricing of Chidozie's share sales and the extent of retained indirect ownership. The broader company announcements outline ongoing regulatory interaction and fresh capital aimed at advancing CNM-Au8. The juxtaposition of insider selling, near-term regulatory milestones and recent financing gives investors multiple data points to consider as they assess the company's near-term outlook.
Where to find further analysis
Investors looking for more in-depth metrics and additional commentary can access eight extra ProTips and detailed financial metrics on InvestingPro, including an analysis of the company’s financial health score.